Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone

Area of Science:

• Biochemistry
• Pharmacology
• Cancer Research

Background:

• Atovaquone (ATO), an FDA-approved antimalarial, exhibits significant antiproliferative effects in various cancer cells.
• ATO's antitumor mechanism involves inhibiting mitochondrial complex III and cellular respiration.

Purpose of the Study:

• To enhance the chemotherapeutic efficacy of ATO by developing mitochondria-targeted conjugates.
• To investigate the effect of varying alkyl chain lengths on ATO's antiproliferative activity and mitochondrial target.

Main Methods:

• Synthesis of triphenylphosphonium-conjugated ATO derivatives (Mito4-ATO, Mito10-ATO, Mito12-ATO, Mito16-ATO).
• Assessment of antiproliferative effects in cancer cells.
• Evaluation of mitochondrial respiration inhibition using oxygen consumption assays.

Main Results:

• Triphenylphosphonium-conjugated ATO significantly enhanced the antiproliferative effect of ATO in cancer cells.
• The alkyl chain length determined the molecular target: Mito4-ATO and Mito10-ATO inhibited both Complex I and Complex III, while Mito12-ATO and Mito16-ATO selectively inhibited Complex I.
• Mitochondrial target shifting was observed, with implications for immunomodulation.

Conclusions:

• Mitochondria-targeted ATO conjugates represent a promising strategy to enhance antitumor efficacy.
• The ability to modulate the inhibition target (Complex I vs. Complex III) offers a novel approach to cancer therapy.
• Potential immunoregulatory roles of mitochondrial target shifting warrant further investigation.